JOURNEY MEDICAL CORP (DERM) Earnings History & Surprises

NASDAQ:DERMUS48115J1097

Current stock price

4.95 USD
+0.09 (+1.85%)
Last:

DERM Earnings overview

Past quarterly earnings results for JOURNEY MEDICAL CORP (DERM), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).

Earnings Snapshot

Next Earnings Date

Upcoming
Release Date
N/A
Period
Q1 / 2026
EPS Estimate
-$0.09
Revenue Estimate
16.431M

Last Reported

Most Recent
Release Date
Mar 25, 2026
Period
Q4 / 2025
EPS Reported
-$0.05
EPS Surprise
21.57%
Revenue Surprise
-16.43%

Beat Rate

Last 8 Quarters
31%
EPS and Revenue beats vs estimates

Quarterly Earnings Historical Results

EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.

QuarterEPSEPS EstEPS SurpriseEPS Q2QRevenueRevenue EstRevenue SurpriseRevenue Q2Q
Q4 2025 -0.05 -0.06 21.57% 69.33% 16.079M 19.24M -16.43% 18.05%
Q3 2025 -0.09 -0.05 -85.76% 47.06% 17.631M 19.231M -8.32% 20.52%
Q2 2025 -0.16 -0.11 -49.39% 5.88% 15.009M 15.232M -1.46% 1.04%
Q1 2025 -0.18 -0.24 25.70% 66.04% 13.139M 12.296M 6.86% 0.84%
Q4 2024 -0.15 -0.36 58.28% -25.00% 13.62M 14.498M -6.06% -10.73%
Q3 2024 -0.17 -0.15 -12.99% -121.25% 14.629M 14.675M -0.31% -57.64%
Q2 2024 -0.17 -0.15 -16.28% 41.38% 14.855M 14.158M 4.92% -13.49%
Q1 2024 -0.53 -0.24 -121.11% 7.02% 13.03M 14.38M -9.39% 6.69%
Q4 2023 -0.12 -0.08 -53.45% 80.00% 15.257M 15.362M -0.68% -4.46%
Q3 2023 0.80 -0.16 606.01% 240.35% 34.539M 17.216M 100.62% 114.26%
Q2 2023 -0.29 -0.34 15.13% 32.56% 17.172M 15.104M 13.69% -6.11%
Q1 2023 -0.57 -0.46 -25.11% -612.50% 12.213M 16.501M -25.99% -47.58%
Q4 2022 -0.60 -0.48 -26.05% 63.41% 15.97M 16.912M -5.57% -8.85%
Q3 2022 -0.57 -0.40 -40.88% -278.12% 16.12M 18.006M -10.47% -17.80%
Q2 2022 -0.43 -0.26 -64.25% - 18.29M 21.734M -15.85% 19.62%
Q1 2022 -0.08 -0.32 74.70% - 23.3M 22.593M 3.13% -
Q4 2021 -1.64 -0.42 -289.00% - 17.52M 20.808M -15.80% -60.66%
Q3 2021 0.32 - - 19.61M - -
Q2 2021 - - 15.29M - 62.31%
Q4 2020 - - 44.531M - -
Q2 2020 - - 9.42M - -

Notes

  • EPS and Revenue values are non-GAAP when available, otherwise GAAP.
  • Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
  • Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
  • Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.

Earnings Q2Q Performance Trends

EPS Historical Q2Q growth and Acceleration

DERM EPS Q2Q GrowthDERM EPS Q2Q GrowthEPS Q2Q Growth Q3/22 Q4/22 Q1/23 Q2/23 Q3/23 Q4/23 Q1/24 Q2/24 Q3/24 Q4/24 Q1/25 Q2/25 Q3/25 Q4/25 Q1/26 Q2/26 Q3/26 Q4/26 0 200 -200 -400 -600

Revenue Historical Q2Q growth and Acceleration

DERM Revenue Q2Q GrowthDERM Revenue Q2Q GrowthRevenue Q2Q Growth Q2/21 Q2/22 Q4/22 Q2/23 Q4/23 Q2/24 Q4/24 Q2/25 Q4/25 Q2/26 Q4/26 0 50 -50 100

Surprise distribution (Last 4 Quarters)

EPS beat statistics

EPS beat (4)
2
Average EPS beat (4)
-21.97%
Max EPS beat (4)
25.70%
Min EPS beat (4)
-85.76%

Revenue beat statistics

Revenue beat (4)
1
Average Revenue beat (4)
-4.84%
Max Revenue beat (4)
6.86%
Min Revenue beat (4)
-16.43%

Analysis

In the last 4 quarters, DERM has beaten EPS estimates in 2 out of 4 releases
DERM has beaten revenue estimates in 1 out of the last 4 releases
In the last 4 quarters, DERM reported -22.0% below the EPS estimates on average.
In the last 4 quarters, DERM reported -4.8% below the revenue estimates on average.

JOURNEY MEDICAL CORP / DERM Earnings FAQ

When did JOURNEY MEDICAL CORP (DERM) report earnings last quarter?

JOURNEY MEDICAL CORP (DERM) last reported earnings on 3/25/2026.

Did JOURNEY MEDICAL CORP (DERM) beat earnings estimates last quarter?

JOURNEY MEDICAL CORP (DERM) beat EPS estimates and missed revenue estimates in the most recent quarter.

How often does JOURNEY MEDICAL CORP (DERM) beat earnings estimates?

In the last 4 quarters, JOURNEY MEDICAL CORP (DERM) has beaten EPS estimates in 2 out of 4 releases.